Aim Immuno Tech Inc. AIM
We take great care to ensure that the data presented and summarized in this overview for AIM ImmunoTech Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AIM
View all-
Vanguard Group Inc Valley Forge, PA2.44MShares$21.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$6.19 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA531KShares$4.71 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny318KShares$2.82 Million0.0% of portfolio
-
State Street Corp Boston, MA173KShares$1.54 Million0.0% of portfolio
-
Verition Fund Management LLC Greenwich, CT162KShares$1.44 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL85.1KShares$755,0050.0% of portfolio
-
Xtx Topco LTD London, X083.5KShares$740,7240.0% of portfolio
-
Morgan Stanley New York, NY76.3KShares$676,9580.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il48.7KShares$431,5690.0% of portfolio
Latest Institutional Activity in AIM
Top Purchases
Top Sells
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Insider Transactions at AIM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2025
|
Thomas K Equels CEO & President |
BUY
Open market or private purchase
|
Direct |
107
+0.27%
|
$749
$7.7 P/Share
|
|
Jun 12
2025
|
Thomas K Equels CEO & President |
BUY
Open market or private purchase
|
Direct |
103
+0.27%
|
$824
$8.7 P/Share
|
|
Apr 11
2025
|
Ted D Kellner Director |
BUY
Open market or private purchase
|
Direct |
1,968,504
+49.99%
|
$0
$0.03 P/Share
|
|
Apr 11
2025
|
Thomas K Equels CEO & President |
BUY
Open market or private purchase
|
Direct |
1,968,504
+33.73%
|
$0
$0.03 P/Share
|
|
Apr 11
2025
|
William M Mitchell Director |
BUY
Open market or private purchase
|
Direct |
196,851
+27.39%
|
$0
$0.03 P/Share
|
|
Apr 04
2025
|
Thomas K Equels CEO & President |
BUY
Open market or private purchase
|
Direct |
41,000
+2.11%
|
$0
$0.06 P/Share
|
|
Apr 04
2025
|
Iii Peter W. Rodino COO, Secretary, Gen. Counsel |
BUY
Open market or private purchase
|
Direct |
500
+0.12%
|
$0
$0.09 P/Share
|
|
Mar 14
2025
|
David I. Chemerow Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,899
+41.16%
|
$0
$0.12 P/Share
|
|
Mar 14
2025
|
Nancy Bryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,899
+13.33%
|
$0
$0.12 P/Share
|
|
Mar 14
2025
|
William M Mitchell Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,899
+12.14%
|
$0
$0.12 P/Share
|
|
Mar 05
2025
|
Thomas K Equels CEO & President |
BUY
Open market or private purchase
|
Direct |
50,000
+2.62%
|
$0
$0.13 P/Share
|
|
Mar 04
2025
|
Thomas K Equels CEO & President |
BUY
Open market or private purchase
|
Direct |
127,334
+3.44%
|
$0
$0.12 P/Share
|
|
Feb 28
2025
|
David I. Chemerow Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,290
+50.0%
|
$0
$0.14 P/Share
|
|
Feb 28
2025
|
William M Mitchell Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+12.11%
|
$0
$0.14 P/Share
|
|
Feb 28
2025
|
Nancy Bryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+13.51%
|
$0
$0.14 P/Share
|
|
Feb 14
2025
|
Nancy Bryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,330
+17.21%
|
$0
$0.12 P/Share
|
|
Feb 14
2025
|
William M Mitchell Director |
SELL
Grant, award, or other acquisition
|
Direct |
43,330
-15.22%
|
$0
$0.12 P/Share
|
|
Jan 31
2025
|
Nancy Bryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,797
+13.52%
|
$0
$0.2 P/Share
|
|
Jan 31
2025
|
William M Mitchell Director |
SELL
Grant, award, or other acquisition
|
Direct |
25,797
-11.52%
|
$0
$0.2 P/Share
|
|
Jan 15
2025
|
William M Mitchell Director |
SELL
Grant, award, or other acquisition
|
Direct |
27,412
-13.73%
|
$0
$0.19 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.41M shares |
|---|---|
| Open market or private purchase | 4.66M shares |
| Grant, award, or other acquisition | 96.5K shares |
|---|---|
| Open market or private sale | 4.58K shares |